Mercer Global Advisors
GYRE icon

Mercer Global Advisors’s Gyre Therapeutics GYRE Stock Holding History

Mercer Global Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28K Buy
+195
New +$1.33K ﹤0.01% 5693

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mercer Global Advisors's GYRE Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 195 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #5693 among its holdings.

46 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Mercer Global Advisors held 195 shares of Gyre Therapeutics worth $1.28K as of Q2 2026.
  • Gyre Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5693 holding.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.